Pactamycin ( NSC 52947 )

Catalog No. M13681 CAS No. 23668-11-3

Pactamycin (NSC 52947) is a potent protein synthesis inhibitor.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
5MG	873	Get Quote
100MG	Get Quote	Get Quote
200MG	Get Quote	Get Quote
500MG	Get Quote	Get Quote
1G	Get Quote	Get Quote

Group Booking Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Pactamycin
Note

Research use only, not for human use.
Brief Description

Pactamycin (NSC 52947) is a potent protein synthesis inhibitor.
Description

Pactamycin (NSC 52947) is a potent protein synthesis inhibitor, inhibits protein synthesis at the translocation step on the 70S ribosome, has activity against Gram-positive and Gram-negative bacteria, and broad antitumor, antiviral, and antiplasmodial activity.
Synonyms

NSC 52947
Pathway

GPCR/G Protein
Target

Antibacterial
Recptor

Antibacterial
Research Area

——
Indication

——

Chemical Information

CAS Number

23668-11-3
Formula Weight

558.62
Molecular Formula

C28H38N4O8
Purity

>98% (HPLC)
Solubility

——
SMILES

InChI=1S/C28H38N4O8/c1-15-9-7-12-20(35)21(15)24(36)40-14-27(39)26(4,38)23(30-19-11-8-10-18(13-19)16(2)33)22(29)28(27,17(3)34)31-25(37)32(5)6/h7-13,17,22-23,30,34-35,38-39H,14,29H2,1-6H3,(H,31,37)
Chemical Name

[(1S,2R,3R,4S,5S)-5-(3-acetylanilino)-4-amino-3-(dimethylcarbamoylamino)-1,2-dihydroxy-3-[(1S)-1-hydroxyethyl]-2-methylcyclopentyl]methyl 2-hydroxy-6-methylbenzoate

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. Bhuyan BK. Biochem Pharmacol. 1967 Aug;16(8):1411-20.
2. Suzuki H, et al. Proc Natl Acad Sci U S A. 1974 Oct;71(10):4259-63.
3. Kappen LS, et al. Biochemistry. 1976 Feb 24;15(4):811-8.
4. Hanessian S, et al. Bioorg Med Chem. 2013 Apr 1;21(7):1775-86.

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

Product			Quantity Required*
Name *			E-mail Address *
Organization *			Phone Number
Remarks